Gene Narcotic Attenuation Program attenuates substance use disorder, a clinical subtype of reward deficiency syndrome

@article{Chen2007GeneNA,
  title={Gene Narcotic Attenuation Program attenuates substance use disorder, a clinical subtype of reward deficiency syndrome},
  author={Thomas J. H. Chen and Kenneth Blum and Roger L. Waite and Brian Meshkin and John Schoolfield and B. Williams Downs and Eric E Braverman and Vanessa Arcuri and Michael Varshavskiy and Seth H. Blum and Julie F. Mengucci and Carolyn Reuben and Tom{\'a}s Palomo},
  journal={Advances in Therapy},
  year={2007},
  volume={24},
  pages={402-414}
}
This study evaluated the effects of a putative activator of brain reward circuitry on outcomes in a 1 -y prospective comprehensive outpatient clinical program. As part of the Gene Narcotic Attenuation Program, Haveos (Synaptamine)™ was administered for the treatment of substance use disorder. Seventy-six patients (45 males and 31 females; mean age, 33 y [standard deviation, 7.0]) who had been given a diagnosis of serious substance use disorder were recruited. After exclusion of 15 patients who… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 20 CITATIONS

Pro-Dopamine Regulator – (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)

  • Journal of reward deficiency syndrome and addiction science
  • 2017
VIEW 2 EXCERPTS
CITES BACKGROUND & METHODS